Ginkgo Biloba: Benefits, Dosage, and What the Research Says

Ginkgo biloba is one of Earth's most ancient tree species, with a fossil record stretching back more than 200 million years. Native to China and long used in traditional East Asian medicine, it has become one of the top-selling botanical supplements in the United States and Europe.

The commercially relevant material is a standardized extract of the distinctive fan-shaped leaves. The most extensively studied preparation is designated EGb761, which is standardized to contain:

• 24% flavonol glycosides - primarily quercetin, kaempferol, and isorhamnetin, responsible for most of the antioxidant activity
• 6% terpene lactones - ginkgolides A, B, C, J, and bilobalide, associated with platelet-activating factor (PAF) antagonism and neuroprotective effects
• Less than 5 ppm ginkgolic acids - the potentially allergenic alkylphenols removed during processing in quality extracts

This standardization matters clinically: nearly all human trial data cited in this article used EGb761 or an equivalent standardized extract at defined concentrations. Raw, unstandardized, or poorly manufactured leaf products cannot be assumed to deliver equivalent activity.

In the United States, ginkgo biloba is sold as a dietary supplement regulated under the Dietary Supplement Health and Education Act (DSHEA). It is not approved by the FDA to diagnose, treat, cure, or prevent any disease.

Ginkgo biloba's two main bioactive fractions appear to act through complementary pathways, which may explain why clinical effects are most consistently observed in populations with existing age-related or circulatory stress rather than in healthy younger adults.

Antioxidant and neuroprotective activity

The flavonol glycosides directly scavenge free radicals - including superoxide, hydroxyl radicals, and nitric oxide - and upregulate protective enzymes such as superoxide dismutase (SOD) and catalase. By reducing oxidative stress in neurons and vascular endothelium, these compounds may help maintain the structural integrity of brain cells under conditions of elevated oxidative burden, such as aging or ischemic stress. Bilobalide, a sesquiterpene lactone unique to ginkgo biloba, has also shown neuroprotective properties in preclinical models, including modulation of GABA-A receptor activity and support for mitochondrial function.

Platelet-activating factor (PAF) antagonism and circulation

Ginkgolides - particularly ginkgolide B - are selective antagonists of platelet-activating factor, a phospholipid mediator involved in platelet aggregation, inflammation, and vasospasm. PAF antagonism is thought to improve cerebral microcirculation by reducing platelet clumping and supporting vasodilation. This same mechanism is also the primary driver of the supplement's clinically significant interaction with anticoagulant and antiplatelet medications (covered in detail in the Safety section).

It is important to note that most mechanistic evidence comes from animal and cell-culture studies. Human clinical trials measure outcomes rather than mechanisms directly, so the proposed pathways above are plausible explanations for observed effects but have not been confirmed mechanistically in humans at supplement doses.

This is the most extensively researched area for ginkgo biloba, and the evidence is strongest - though still modest - in adults who already have mild cognitive impairment (MCI) or early dementia.

What the research shows in MCI and dementia

Multiple independent meta-analyses of randomized controlled trials reach similar conclusions. A 2015 systematic review and meta-analysis of nine RCTs involving 2,561 patients found that EGb761 at 240 mg per day was able to stabilize or slow decline in cognition, activities of daily living (ADLs), neuropsychiatric behavior, and global clinical impression of change over 22-26 weeks compared with placebo.¹ Neuropsychiatric symptoms - including agitation and anxiety - showed some of the most consistent benefits in that analysis.

A 2014 meta-analysis of seven placebo-controlled RCTs enrolling 2,684 patients found statistically significant improvements in cognition (standardized mean difference -0.52; 95% CI -0.98 to -0.05), daily living activities, and clinical global rating, with comparable rates of adverse events between EGb761 and placebo groups - indicating that tolerability was good.⁴

A larger 2016 meta-analysis covering 21 RCTs and 2,608 participants found that ginkgo biloba combined with standard care improved Mini-Mental State Examination (MMSE) scores by 2.39 points in Alzheimer's disease (MD 2.39; 95% CI 1.28-3.50; P<0.0001) and by 1.90 points in MCI (MD 1.90; 95% CI 1.41-2.39; P<0.00001) at 24 weeks. Activities of daily living and adverse event profiles also favored ginkgo biloba.³

An overview synthesizing 12 systematic reviews concluded that ginkgo biloba extract shows potentially beneficial effects for people with dementia when administered at doses above 200 mg per day for at least five months. Doses below 200 mg per day and study durations shorter than 22 weeks showed insufficient evidence of benefit.⁵

Does ginkgo biloba work for cognitively healthy adults?

The controlled trial evidence here tells a clearly different story. A meta-analysis analyzing randomized trials involving 1,132 cognitively intact participants found near-zero and statistically non-significant effect sizes for memory (d = -0.04), executive function (d = -0.05), and attention (d = -0.08). These null findings held regardless of participant age, trial duration, or dose studied.²

The Ginkgo Evaluation of Memory (GEM) trial - a large double-blind, placebo-controlled study following more than 3,000 adults aged 72-96 over a median of 6.1 years with EGb761 at 240 mg per day - found no reduction in rate of cognitive decline compared with placebo across memory, attention, language, and executive function domains.⁹

The honest summary: Clinical research suggests that ginkgo biloba at 240 mg per day may provide modest support for cognitive function and daily activities in adults who already show signs of early cognitive decline. The research does not support using ginkgo biloba to sharpen memory or enhance cognition in healthy adults.

A smaller body of clinical evidence suggests that ginkgo biloba extract may help support a calmer stress response in certain populations, though this area requires more research before strong conclusions are appropriate.

What the research shows

One well-designed double-blind, placebo-controlled RCT by Woelk and colleagues randomized 107 adults with generalized anxiety disorder (GAD) or adjustment disorder with anxious mood to either 480 mg per day EGb761, 240 mg per day EGb761, or placebo for four weeks. Both active treatment groups showed significant reductions in Hamilton Anxiety Rating Scale (HAMA) scores compared with placebo - with p=0.0003 for the higher-dose group and p=0.01 for the lower-dose group. A statistically significant dose-response trend (p=0.003) was also observed, suggesting the relationship was not a statistical artifact. The extract was described as safe and well tolerated across all groups.⁷

Consistent with these findings, meta-analyses of EGb761 in dementia populations also report reductions in neuropsychiatric symptoms including agitation and anxiety, which may reflect a shared mechanism.¹

This evidence base is currently limited to a single anxiety-specific RCT of short duration. More research in larger populations and with longer follow-up is needed before this benefit can be considered well established for the general supplement consumer.

Two popular uses of ginkgo biloba - tinnitus relief and peripheral circulation support - are not well supported by current controlled trial evidence.

Tinnitus

Ginkgo biloba is frequently marketed for tinnitus (ringing in the ears), but the highest-quality synthesis of the evidence reaches a cautious conclusion. A 2022 Cochrane systematic review examined 12 randomized controlled trials involving 1,915 participants and found "little to no effect" on tinnitus symptom severity (Tinnitus Handicap Inventory scores) compared with placebo, with the overall quality of evidence rated as very uncertain across all measured outcomes.⁶ The review found no serious adverse events such as bleeding or seizures across the included studies. While some individual studies report positive effects in specific subgroups - particularly those with tinnitus associated with dementia or high anxiety - there is currently insufficient evidence to recommend ginkgo biloba for tinnitus as a primary complaint.

Peripheral artery disease and intermittent claudication

For intermittent claudication (leg cramping from reduced blood flow in peripheral artery disease), a 2013 Cochrane systematic review and meta-analysis of 14 RCTs involving 739 participants found no clinically meaningful benefit. The mean improvement in absolute claudication distance with ginkgo biloba over placebo was approximately 64.5 meters - a difference that did not reach statistical significance (P=0.06) - and the authors noted that publication bias likely inflated even this modest estimate.⁸

For both conditions, current evidence does not support ginkgo biloba as a first-line or established intervention.